Lp(a) Drug Race Aims to Prove Heart Disease Prevention
TL;DR Summary
Rival drugmakers, led by Novartis, are sprinting to prove that lowering Lp(a) — a genetic risk factor affecting about 1 in 5 people — can prevent heart disease, a space with no approved therapies and a potential multi‑billion market as late-stage trials seek to show fewer cardiovascular events.
- New treatments for common cardiovascular risk factor near the market, with billions at stake STAT
- Why PCPs Should Check Lipoprotein(a) Medscape
- Key data on a new class of cardio drugs are coming STAT
- Key data on a new class of cardiovascular drugs expected soon UA.NEWS
- Lipoprotein (a) goes mainstream: Test now—outcome trials coming soon MDLinx
Reading Insights
Total Reads
1
Unique Readers
2
Time Saved
2 min
vs 3 min read
Condensed
88%
413 → 48 words
Want the full story? Read the original article
Read on STAT